Biotechnology stocks are doing extremely well on the exchanges today, as a few biotech companies around the world announced clinical trial successes this morning. AmpliPhi Biosciences Corp. (AMX:APHB) has shown a large rally, as the company reports positive topline results for its extremely ill patients that were unresponsive to antibiotic treatment. APHB achieved treatment success and significant improvement of baseline signs and symptoms of these patients.
Paul C. Grint, AmpliPhi’s CEO said:
“I am very encouraged by these initial results for treatment with AB-SA01 or AB-PA01 in severely ill patients who were not responding to antibiotics […] We look forward to treating up to an additional 20 patients during the first half of 2018 and discussing our findings with the FDA to determine a development path forward to registration. Our ongoing dialogue with infectious disease thought leaders continues to indicate growing support for our program.
Bacteriophage therapy has been around for the past hundred years but with our new advancement in technology and DNA sequencing, we are now able to produce products that can be given intravenously. Antibiotic resistance has become a growing crisis in the medical field. For the smallest of infections, patients are put on multiple rounds and variations of different antibiotics, before the infection is actually killed.
This new development by APHB has the possibility to save hundreds of thousands of lives of those that are severely ill and have antibiotic resistance.
Now, severely ill patients can receive treatment in the U.S and Australia, in emergency situations. However, these patients must be critical as it is still deemed experimental and unapproved but can be an attempt to save the patient’s life when the doctor has no alternative options.
At the time of reporting, AmpliPhi Biosciences is up 16% for the day, selling at $1.30 a share.
Another Biotechnology company, Cellect Biotechnology Ltd (NASDAQ:APOP) is up 48% today, as it announced this morning as well, positive clinical results on its stem cell trial.
Featured Image: twitter
